Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eli Lilly’s Cymbalta improves anxiety symptoms in trial
In this nine-week study, Cymbalta significantly improved core anxiety symptoms such as anxious mood, fears and tension by 51% in patients taking 60mg/day and by 50% in patients
In this nine-week study, Cymbalta significantly improved core anxiety symptoms such as anxious mood, fears and tension by 51% in patients taking 60mg/day and by 50% in patients
The analysis of the data showed a trend in favor of Oncophage for recurrence-free survival, the study’s primary endpoint, but a trend against Oncophage for overall survival, the
The decision follows an appeal procedure undertaken by Novartis in December 2005 after the Committee for Medicinal Products for Human Use (CHMP) recommended that the European Commission not
If final European approval is granted, it is likely to be finalized in the second quarter of 2006. The product combines the Allergan’s eye drops Lumigan that reduces
In the 41 patient trial, patients were given either a single dose of the drug known only as 4975 or placebo, which was instilled (dripped by syringe) into
The company said that it is yet to have additional discussions with the FDA but that it may be necessary to conduct a second clinical trial in order
Merck pulled out of the bidding for its German rival saying that an offer in excess of Bayer’s E16.3 billion, or E86 per share, would not be justified.
This study is designed to generate the type of safety and efficacy data that could form the basis of a new drug application (NDA). The 30-week open-label, non-inferiority
Ranexa is approved as second-line treatment for chronic angina and has antianginal and anti-ischemic effects that do not depend upon reductions in heart rate or blood pressure. “This
Under the terms of the agreement, BioWa will provide Genentech with exclusive commercial rights to use the technology for multiple antibodies. In return, BioWa will receive technology access